Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Vaccine    symbols : Vir    save search

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Published: 2023-09-20 (Crawled : 12:00) - globenewswire.com
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -0.3% H: 0.61% C: -4.58%

vir-1388 vaccine cell hiv
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
Published: 2023-05-02 (Crawled : 13:00) - globenewswire.com
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -0.6% H: 0.52% C: -1.56%

vaccine cell grant hiv platform
Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies
Published: 2021-12-14 (Crawled : 23:00) - globenewswire.com
XNCR | $18.65 -1.58% 130K twitter stocktwits trandingview |
Health Technology
| | O: 3.02% H: 6.19% C: 5.15%
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: 6.71% H: 10.12% C: 5.09%

monoclonal antibodies preclinical sars-cov-2 vaccine antibody pre-clinical
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Published: 2021-12-07 (Crawled : 14:00) - prnewswire.com
GLAXF | $20.2 510 twitter stocktwits trandingview |
Health Technology
| | O: 5.22% H: 0.0% C: -1.25%
JNJ | News | $146.39 0.45% 1.8M twitter stocktwits trandingview |
Health Technology
| | O: 2.13% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K twitter stocktwits trandingview |
Health Technology
| | O: 0.14% H: 0.0% C: 0.0%
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -6.42% H: 8.6% C: 8.45%
SRNE | $0.024 57K twitter stocktwits trandingview |
Health Technology
| | O: 6.57% H: 14.77% C: 11.21%
RDHL | $0.425 1.0% 120K twitter stocktwits trandingview |
Health Technology
| | O: 0.37% H: 10.37% C: 9.63%

covid vaccine
Global $9.5 Billion Influenza Vaccines Market to 2027
Published: 2021-07-27 (Crawled : 11:00) - prnewswire.com
GSK | $39.685 1.06% 380K twitter stocktwits trandingview |
Health Technology
| | O: 0.41% H: 1.0% C: 0.87%
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -0.68% H: 2.23% C: -0.76%
SNY | News | $46.34 2.09% 620K twitter stocktwits trandingview |
Health Technology
| | O: -0.54% H: 0.65% C: 0.49%

vaccine influenza
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
Published: 2021-06-23 (Crawled : 11:00) - vbivaccines.com
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -0.34% H: 2.23% C: -0.86%
VBIV | $0.639 1.48% 43K twitter stocktwits trandingview |
Health Technology
| | O: 1.03% H: 1.53% C: -0.76%

hepatitis phase 1 positive vbi-2601 vaccine liver phase 1b phase 2b chronic hepatitis b
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -1.09% H: 0.38% C: 0.04%
VBIV | $0.639 1.48% 43K twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 7.66% C: 7.66%
ALNY | News | $146.34 0.81% 64K twitter stocktwits trandingview |
Health Technology
| | O: 0.67% H: 1.12% C: 0.43%

treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform– Culmination of a decade-long collaboration with Oregon Health & Science University and the Bill & Melinda Gates Foundation –
Published: 2021-01-06 (Crawled : 18:00) - biospace.com/
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -0.57% H: 4.54% C: 1.26%

collaboration biotech vaccine trial phase 3 phase 1 phase 2 decades
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
Published: 2021-01-06 (Crawled : 13:03) - globenewswire.com
VIR | $8.02 0.75% 140K twitter stocktwits trandingview |
Health Technology
| | O: -0.57% H: 4.54% C: 1.26%

biotech vaccine trial phase 3 phase 1 phase 2 platform
Gainers vs Losers
79% 21%

Top 10 Gainers
AGBA | News | $1.22 205.0% 86M twitter stocktwits trandingview |
Finance

EGOX | $0.0606 68.33% 250M twitter stocktwits trandingview |

NVFY | $3.45 63.51% 20M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.98 36.55% 27M twitter stocktwits trandingview |
Commercial Services

CHRO | $1.66 35.51% 70K twitter stocktwits trandingview |
n/a

INDO | $5.43 33.09% 10M twitter stocktwits trandingview |
Energy Minerals

PAPL | $2.07 26.22% 550K twitter stocktwits trandingview |

RWOD | $10.08 26.05% 5.6M twitter stocktwits trandingview |
n/a

AULT | $0.304 25.57% 47M twitter stocktwits trandingview |
Manufacturing

HUSA 4 | $2.07 23.95% 2.1M twitter stocktwits trandingview |
Energy Minerals


Your saved searches
Save your searches and get alerts when important news are released.